Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2026-05-20 Director's Dealing
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Oncoinvent ASA: Grant of share options to member of the Board following AGM - Attachment: PDMR_notifications_20_May_2026_grant_of_board_options.pdf
Director's Dealing Classification · 92% confidence The document consists of multiple “NOTIFICATION BY PRIMARY INSIDERS/RELATED PARTIES” entries detailing share option grants to board members and the chairperson – clearly insider transactions by company directors. This aligns with the definition of Director’s Dealing (insider trades).
2026-05-20 English
Oncoinvent ASA: Grant of share options to member of the Board following AGM
Director's Dealing Classification · 85% confidence The document is a PDMR notification under EU Market Abuse Regulation disclosing share option grants to board members (insider transactions) following the AGM. It reports personal share-related transactions by company directors/executives. This matches the Director’s Dealing category (DIRS).
2026-05-20 English
Oncoinvent ASA: Minutes from Annual General Meeting - Attachment: Oncoinvent_ASA_Minutes_of_Annual_General_Meeting_20_May_2026_signed.pdf
AGM Information Classification · 80% confidence The document is the full minutes of the Annual General Meeting of Oncoinvent ASA, detailing agenda items, resolutions, votes, and authorizations. It is not merely an announcement or summary nor an annual report or regulatory filing, but the core AGM materials — the official record of the meeting.
2026-05-20 Norwegian Bokmål
Oncoinvent ASA: Minutes from Annual General Meeting
Report Publication Announcement Classification · 90% confidence The document is a short press release (under 5,000 characters) notifying stakeholders that the minutes from the Annual General Meeting are attached and available online. It does not contain the full minutes or substantive AGM materials but rather announces their publication. Per the “menu vs meal” rule, this is an announcement of publication of a report rather than the report itself.
2026-05-20 English
Oncoinvent ASA: Share capital decrease completed
Declaration of Voting Results & Voting Rights Announcements
2026-05-05 Norwegian
Oncoinvent presents corporate update in live webcast
Investor Presentation Classification · 75% confidence The document is an announcement for a live webcast “corporate update” including presenters, highlights, and a link for investors to view presentation materials. It is not the full financial results or report itself, nor an AGM, proxy, or dividend notice. It clearly serves as an investor presentation invitation (with the deck to follow on the website). Therefore it best matches the “Investor Presentation” category.
2026-04-29 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.